GLP-1 and Incretin Drugs

GLP-1 is a peptide proven to be an effective treatment for diabetes and weight management. However, taking any peptide that has not been approved as a medication is risky and potentially ineffective.

Off-label use of medications like Ozempic, Wegovy, Mounjaro, and Zepbound is becoming increasingly common to address weight management, insulin resistance, and diabetes related complications in type 1 diabetes. New expert recommendations provide a framework for safe use while large trials are ongoing. 

Choosing a diabetes medication that’s right for you depends on your needs. If an incretin therapy like Mounjaro or Ozempic is what you need to manage your blood sugar and support your overall health, then there’s no reason to delay starting one.

Ozempic (semaglutide) is a GLP-1 medication used for blood sugar management that also provides heart and kidney protection in people with type 2 diabetes. It’s available as a once-weekly injectable, and as of May 2026, a once-daily pill.

For people seeking an oral GLP-1 medication, Foundayo is now available in the U.S.

Insurance issues and side effects are some of the reasons people need to stop taking a GLP-1 drug for diabetes or weight management. Here’s how to navigate the transition and protect your health.